KinSea Lead Discovery — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

KinSea Lead Discovery is an early-stage biotech leveraging the unique biodiversity of the Arctic Ocean to discover novel small-molecule therapeutics. Its lead program targets pan-mutant FLT3 for acute myeloid leukemia, with a compound that has reportedly passed animal proof-of-concept. The company is a spin-off from leading Norwegian academic institutions and is backed by European venture capital, having secured seed financing and a significant grant from Innovation Norway.

OncologyHematologic Cancer

Technology Platform

A marine bioprospecting and drug discovery platform focused on isolating, characterizing, and optimizing bioactive natural products from Arctic Ocean organisms. It integrates marine biology, natural product chemistry, high-throughput screening, and medicinal chemistry.

Opportunities

The Arctic marine ecosystem is a vast, underexplored source of novel chemical scaffolds, offering a significant first-mover advantage in natural product drug discovery.

A successful pan-mutant FLT3 inhibitor addresses a clear unmet need in AML and could command a premium in a growing targeted therapy market.

Validation of the lead program would de-risk the entire platform, enabling partnerships and pipeline expansion into other oncology and non-oncology indications.

Risk Factors

High technical risk associated with advancing a natural product-derived compound through preclinical development and clinical trials, including potential challenges with synthesis, scalability, and pharmacokinetics.

The company is pre-revenue and dependent on milestone-driven grant funding and venture capital, with runway contingent on achieving key objectives.

Intense competition in the FLT3 inhibitor space from larger, well-funded biopharma companies with more advanced clinical programs.

Competitive Landscape

KinSea competes in the crowded and rapidly evolving FLT3 inhibitor space, dominated by large pharma (Astellas with gilteritinib, Daiichi Sankyo with quizartinib) and numerous biotechs developing next-generation agents. Its key differentiator is the novel marine-derived chemical scaffold, which may offer superior pan-mutant activity and a unique resistance profile. However, it trails many competitors in development stage, requiring significant capital and time to reach clinical proof-of-concept.

More companies in Small Molecule Drugs →More companies in Norway →